Long-read SMRT Sequencing for New Insights into Genomes, Epigenomes and Transcriptomes

SMRT® Sequencing is a DNA sequencing technology characterized by long read lengths and high consensus accuracy, regardless of the sequence complexity or GC content. These characteristics can be harnessed to gain more comprehensive views of genomes, transcriptomes and epigenomes.
Join Pacific Biosciences’ Chief Scientific Officer, Jonas Korlach, as he discusses the scientific value of >10 kb, unbiased sequencing reads for an expanding range of applications including:

• Advantages of long reads in de novo genome assembly
• Resolving the various forms of structural genomic variation, long-range haplotype phasing
• Ability to identify modified DNA bases for epigenetic studies
• Ability to perform full-length transcript sequencing to identify isoforms and splice variants
• Full-length 16S rRNA sequencing and long-read functional Metagenomic

Dr Jonas Korlach

Dr. Korlach was appointed Chief Scientific Officer at PacBio in July 2012. He co-invented the SMRT technology with PacBio Founder and Chief Technology Officer Steve Turner, when the two were graduate students at Cornell University. Dr. Korlach joined PacBio as the company’s eighth employee in 2004. He is the recipient of multiple grants, an inventor on 42 issued U.S. patents, and an author of numerous scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. He received both his Ph.D and M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.